CNE100004ZP2
CNE100004ZP2
LIAONING CHENGDA BIOTECHNOLOGY
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 8.83B EUR | 8.12B EUR | 10.25B EUR | 10.73B EUR |
Enterprise Value | 3.59B EUR | 4.53B EUR | 6.57B EUR | 6.37B EUR |
Valuation Multiples | ||||
Trailing P/E | 212x | 31,352.34x | 676.89x | 120.17x |
Forward P/E | 39.26x | -- | -- | -- |
Price to Sales | 6.49x | 8.35x | 11.19x | 10.72x |
Price to Book | 0.93x | 0.87x | 1.1x | 1.15x |
EV/Revenue | 2.64x | 4.66x | 7.17x | 6.36x |
EV/EBITDA | 18.88x | 47.37x | 75.61x | 38.52x |
Price to FCF (P/FCF) | -- | 83.73x | 151.7x | 185.21x |
EV/FCF | -- | 46.74x | 97.21x | 110.02x |
FCF Yield | -0.7% | 1.19% | 0.66% | 0.54% |